A key decision for a biotechnology company is whether to out-license or self-market a product. Profit shares or the retention of some marketing rights offer a less binary path, but with potentially disparate outcomes from these decisions, even past experience makes determining the optimal strategy a conundrum.
In 2007, Microbia, Inc., a private biotechnology company with limited drug development and commercialization experience, licensed its lead drug to...








